Abstract
Background The 2022-2023 global mpox outbreak primarily affected gay, bisexual, and other men who have sex with men (GBM). It was met with swift community and public health responses. The relative impact of GBM’s reductions in sexual partners, contact tracing/isolation, and vaccination on transmission in Canadian cities remain unknown.
Methods We estimated changes in sexual behaviours during the outbreak using 2022 data from the Engage Cohort Study which recruited self-identified GBM in Montréal, Toronto, and Vancouver (n=1,445). The numbers of sexual partners in the past 6 months (P6M) were modeled using negative binomial regressions. A transmission-dynamic compartmental model was calibrated to surveillance data. We estimated the averted fraction of new infections attributable to reductions in sexual partners, contact tracing/isolation, and first-dose vaccination, versus an unmitigated epidemic scenario, in each of the three cities.
Results The empirical estimates of sexual behaviours changes were imprecise: 20% (RR=0.80; 95% credible intervals [95%CrI]: 0.47-1.36) fewer sexual partners among those reporting ≤7 partners (P6M) and 33% (RR=0.67; 95%CrI: 0.31-1.43) fewer among those with >7 partners (P6M). Compared to the unmitigated epidemics, we estimated that the three interventions combined avert 46%-58% of cases. Reductions in sexual partners, contact tracing/isolation prevented approximately 12% and 14% of cases, respectively. Vaccination’s effect varied across cities by start date and coverage, with 21%-39% mpox infections prevented.
Conclusions Reduction in sexual activity, contact tracing/isolation, and vaccination all contributed to accelerating epidemic control and infections averted. Early vaccination had the largest impact.
Competing Interest Statement
JC reports research grants from Gilead Sciences Canada and ViiV Healthcare, all outside of the submitted work. MM-G reports contractual arrangements from the World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and the Public Health Agency of Canada, all outside of the submitted work. TAH reports educational grants from being an Advisory Committee member for the Canadian Institutes of Health Research (CIHR)'s Institute of Infection and Immunity and funds for community engagement events from ViiV Healthcare and Gilead Sciences Canada, all outside of the submitted work. DHST's institution has received investigator-initiated grants from Abbvie and Gilead, and support for participation in clinical trials sponsored by Glaxo Smith Kline. All other authors report no conflict of interest.
Funding Statement
This work was supported by the Canadian Network for Modelling Infectious Diseases (CANMOD) to SM, MI, and MM-G, grants from the Canadian Institutes of Health Research (CIHR, #495171) to MI, SM, HS, and MM-G, and grants from the University of Toronto Emerging Infections and Pandemic Consortium Mpox Rapid Research Response to SM and DHST. MM-G's research program is funded by a Canada Research Chair (Tier 2) in Population Health Modelling. FX acknowledges studentships from the McGill Center for Viral Diseases and the McGill Faculty of Medicine and Health Sciences. TAH received support from a Chair in Gay and Bisexual Men's Health from the Ontario HIV Treatment Network. SM's research program is funded by a Canada Research Chair (Tier 2, CRC Number 950-232643) in Mathematical Modelling and Program Science. DG's research program is funded by a Canada Research Chair (Tier 2) in Sexual and Gender Minority Health. DHST is supported by a Canada Research Chair (Tier 2) in HIV Prevention and STI Research. JK acknowledges support from the Natural Sciences and Engineering Research Council of Canada Doctoral Award. NL is supported with Scholar Awards from the Michael Smith Foundation for Health Research (#5209, #16863). SS-S is supported by a CIHR postdoctoral fellowship award. The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Office of the Faculty of Medicine and Health Sciences at McGill University gave ethnical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
